FDA's NDA And BLA Approvals: Abilify Mycite, Mepsevii, Hemlibra
Executive Summary
Original new drugs and biologics recently approved by US FDA.
You may also be interested in...
Finance Watch: The Year's Biggest IPO And A Post-ASH Offering Splash
Public Company Edition: Denali launched this year's largest biopharma IPO. Also, Valeant sold notes to retire older debt, while bluebird, Blueprint and others capitalized on data presented at ASH.
FDA Approves First Digital Pill: Otsuka/Proteus' Abilify MyCite
Otsuka plans a slow, measured launch of Abilify MyCite, developed with Proteus Health. The product includes an ingested sensor that sends a signal to a wearable patch and an app that tracks ingestion, activity and mood to potentially improve management of psychiatric care.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.